DE3129714A1 - Anti-psychotikum - Google Patents
Anti-psychotikumInfo
- Publication number
- DE3129714A1 DE3129714A1 DE19813129714 DE3129714A DE3129714A1 DE 3129714 A1 DE3129714 A1 DE 3129714A1 DE 19813129714 DE19813129714 DE 19813129714 DE 3129714 A DE3129714 A DE 3129714A DE 3129714 A1 DE3129714 A1 DE 3129714A1
- Authority
- DE
- Germany
- Prior art keywords
- trans
- lisuride
- dihydro
- effects
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000000561 anti-psychotic effect Effects 0.000 title abstract description 3
- 238000011282 treatment Methods 0.000 claims abstract description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 abstract description 20
- 229960004558 terguride Drugs 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 15
- 201000000980 schizophrenia Diseases 0.000 abstract description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 4
- 229960001076 chlorpromazine Drugs 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 102000015554 Dopamine receptor Human genes 0.000 description 3
- 108050004812 Dopamine receptor Proteins 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 208000009132 Catalepsy Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000030663 Libido disease Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 206010047853 Waxy flexibility Diseases 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960003587 lisuride Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- KWMLJOLKUYYJFJ-GASJEMHNSA-N (2xi)-D-gluco-heptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C(O)=O KWMLJOLKUYYJFJ-GASJEMHNSA-N 0.000 description 1
- AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical class O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013496 Disturbance in attention Diseases 0.000 description 1
- 208000001287 Galactorrhea Diseases 0.000 description 1
- 206010017600 Galactorrhoea Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000001517 counterregulatory effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- CVQFAMQDTWVJSV-BAXNFHPCSA-N lisuride maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 CVQFAMQDTWVJSV-BAXNFHPCSA-N 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003196 psychodysleptic agent Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813129714 DE3129714A1 (de) | 1981-07-23 | 1981-07-23 | Anti-psychotikum |
| DE8282730092T DE3273177D1 (en) | 1981-07-23 | 1982-07-02 | Trans-dihyldrolisuride antipsychotic |
| AT82730092T ATE22010T1 (de) | 1981-07-23 | 1982-07-02 | Antipsychotische trans-dihydrolisuride. |
| EP82730092A EP0071563B1 (en) | 1981-07-23 | 1982-07-02 | Trans-dihyldrolisuride antipsychotic |
| JP57125224A JPS5824520A (ja) | 1981-07-23 | 1982-07-20 | 精神病治療薬 |
| IE1752/82A IE54257B1 (en) | 1981-07-23 | 1982-07-22 | Trans-dihydrolisuride antipsychotic |
| ZA825314A ZA825314B (en) | 1981-07-23 | 1982-07-23 | Trans-dihydrolisuride antipsychotic |
| US06/401,427 US4522820A (en) | 1981-07-23 | 1982-07-23 | Trans-dihydrolisuride antipsychotic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19813129714 DE3129714A1 (de) | 1981-07-23 | 1981-07-23 | Anti-psychotikum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3129714A1 true DE3129714A1 (de) | 1983-02-10 |
Family
ID=6137904
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19813129714 Withdrawn DE3129714A1 (de) | 1981-07-23 | 1981-07-23 | Anti-psychotikum |
| DE8282730092T Expired DE3273177D1 (en) | 1981-07-23 | 1982-07-02 | Trans-dihyldrolisuride antipsychotic |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8282730092T Expired DE3273177D1 (en) | 1981-07-23 | 1982-07-02 | Trans-dihyldrolisuride antipsychotic |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4522820A (enExample) |
| EP (1) | EP0071563B1 (enExample) |
| JP (1) | JPS5824520A (enExample) |
| AT (1) | ATE22010T1 (enExample) |
| DE (2) | DE3129714A1 (enExample) |
| IE (1) | IE54257B1 (enExample) |
| ZA (1) | ZA825314B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0159522A1 (de) * | 1984-03-16 | 1985-10-30 | Schering Aktiengesellschaft | 3-(6-Methylergolin-8 alpha-yl)-1.1-diethyl-Harnstoff als Antihypertensivum |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2112382B (en) * | 1981-11-06 | 1985-03-06 | Erba Farmitalia | Ergoline derivatives |
| EP0208417A3 (en) * | 1985-06-12 | 1989-09-06 | SPOFA Spojené Podniky Pro Zdravotnickou Vyrobu | Use of 1-(8-alpha-ergolinyl)-3,3-diethyl urea derivatives in the treatment of endometritis |
| EP2083008A1 (en) * | 2007-12-07 | 2009-07-29 | Axxonis Pharma AG | Ergoline derivatives as selective radical scavengers for neurons |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH573936A5 (enExample) * | 1971-08-05 | 1976-03-31 | Spofa Vereinigte Pharma Werke | |
| DE2359128A1 (de) * | 1973-11-24 | 1975-06-12 | Schering Ag | Arzneimittel auf basis von lisurid und dessen physiologisch vertraeglichen salzen |
-
1981
- 1981-07-23 DE DE19813129714 patent/DE3129714A1/de not_active Withdrawn
-
1982
- 1982-07-02 DE DE8282730092T patent/DE3273177D1/de not_active Expired
- 1982-07-02 AT AT82730092T patent/ATE22010T1/de not_active IP Right Cessation
- 1982-07-02 EP EP82730092A patent/EP0071563B1/en not_active Expired
- 1982-07-20 JP JP57125224A patent/JPS5824520A/ja active Granted
- 1982-07-22 IE IE1752/82A patent/IE54257B1/en not_active IP Right Cessation
- 1982-07-23 US US06/401,427 patent/US4522820A/en not_active Expired - Lifetime
- 1982-07-23 ZA ZA825314A patent/ZA825314B/xx unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0159522A1 (de) * | 1984-03-16 | 1985-10-30 | Schering Aktiengesellschaft | 3-(6-Methylergolin-8 alpha-yl)-1.1-diethyl-Harnstoff als Antihypertensivum |
| US4593032A (en) * | 1984-03-16 | 1986-06-03 | Schering Aktiengesellschaft | Terguride as antihypertensive |
Also Published As
| Publication number | Publication date |
|---|---|
| DE3273177D1 (en) | 1986-10-16 |
| EP0071563B1 (en) | 1986-09-10 |
| IE821752L (en) | 1983-01-23 |
| ATE22010T1 (de) | 1986-09-15 |
| JPS5824520A (ja) | 1983-02-14 |
| JPH0352446B2 (enExample) | 1991-08-12 |
| EP0071563A1 (en) | 1983-02-09 |
| US4522820A (en) | 1985-06-11 |
| IE54257B1 (en) | 1989-08-02 |
| ZA825314B (en) | 1983-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AT401615B (de) | Verwendung von speziellen 5ht3-antagonisten zur herstellung von arzneimitteln | |
| DE69213814T2 (de) | Melatoninderivate zur Behandlung von Schlafstörungen und zur Pre-Anästhesie | |
| DE68919358T2 (de) | Zusammensetzung zur behandlung der schizophrenie. | |
| DE3876877T2 (de) | Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus. | |
| EP0599307B1 (de) | Johanniskraut-Trockenextrakt, Verfahren zu seiner Herstellung und seine Verwendung | |
| DE60122015T2 (de) | Behandlung affektiver störungen durch kombinierte wirkung eines nikotinischen rezeptoragonisten und einer monoaminergischen substanz | |
| DE3502041A1 (de) | Verwendung von dipeptidderivaten zur behandlung posttraumatischer nervenschaeden | |
| EP0185210B1 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten | |
| DE69420776T2 (de) | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer | |
| EP0236951A2 (de) | Verwendung von Diphenylhydantoin und seinen Derivaten zur Herstellung eines pharmazeutischen Mittels zur Behandlung von Immunerkrankungen | |
| DE3415394A1 (de) | Medikament gegen ovarialinsuffizienz | |
| DE2359128A1 (de) | Arzneimittel auf basis von lisurid und dessen physiologisch vertraeglichen salzen | |
| DE2206570B2 (de) | Verwendung von ( + ) - Catechin | |
| DE3129714A1 (de) | Anti-psychotikum | |
| DE69127285T2 (de) | Verwendung von verbindungen zur behandlung von altersbedingtem gedächtnisschwund und anderen kognitiven störungen | |
| DE69125204T2 (de) | Therapeutische Anwendung von Histamin-H3-Agonisten, neue Wirkstoffe und Verwendung zur Herstellung von Arzneimitteln | |
| DE10163667B4 (de) | Verwendung von Desoxypeganin zur Behandlung der klinischen Depression | |
| DE19726871C1 (de) | Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe | |
| DE60203106T2 (de) | Azolylcarbynol-derivative von aryl (oder heteroaryl) zur behandlung von atemwegserkrankungen | |
| DE69725613T2 (de) | Neue therapeutische verwendung eines thienylcyclohexylaminderivates | |
| DE69004529T2 (de) | Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen. | |
| EP0401653A2 (de) | Verwendung von Naftopidil zur Therapie der Dysurie bei benigner Prostata-Hyperthrophie | |
| DE69426317T2 (de) | Verwendung von Beta-Naphthochinonderivaten zur Hemmung von Blutplättchen-Aggregation | |
| EP0417637A2 (de) | Verwendung von Dopamin-Autorezeptor-Agonisten bei der Behandlung von Drogenabhängigkeit | |
| DE69214647T2 (de) | Verwendung von atipamezol zur behandlung der männlichen sexuellen impotenz |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8141 | Disposal/no request for examination |